Complete remission in severe lupus nephritis: Assessing the rate of loss in proteinuria

Nephrology Dialysis Transplantation

Volumn 27, Issue 7, 2012, Pages 2813-2819

  Korbet, Stephen M ^a   Lewis, Edmund J ^a  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

proteinuria; remission; severe lupus nephritis

Indexed keywords

CREATININE; CYCLOPHOSPHAMIDE; PREDNISONE;

ADULT; ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DISEASE SEVERITY; FEMALE; HUMAN; LOSS IN PROTEINURIA; LUPUS ERYTHEMATOSUS NEPHRITIS; MAJOR CLINICAL STUDY; MALE; MEMBRANOUS GLOMERULONEPHRITIS; PLASMAPHERESIS; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEINURIA; REMISSION; RENAL SYSTEM PARAMETERS; TREATMENT DURATION; TREATMENT RESPONSE;

ADULT; FEMALE; FOLLOW-UP STUDIES; HUMANS; LUPUS NEPHRITIS; MALE; PLASMAPHERESIS; PROGNOSIS; PROSPECTIVE STUDIES; PROTEINURIA; REMISSION INDUCTION; TIME FACTORS;

EID: 84864399920     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfr741     Document Type: Article

References (25)

1. Appel GB, Cohen DJ, Pirani CL et al. Long-term follow-up of patients with lupus nephritis. A study based on the classification of the World Health Organization. Am J Med 1987; 83: 877-885.
2. Fraenkel L, MacKenzie T, Joseph L et al. Response to treatment as a predictor of longterm outcome in patients with lupus nephritis. J Rheumatol 1994; 21: 2052-2057.
3. Levey AS, Lan SP, Corwin HL et al. Progression and remission of renal disease in the Lupus Nephritis Collaborative Study. Results of treatment with prednisone and short-term oral cyclophosphamide. Ann Intern Med 1992; 116: 114-123.
4. Chen YE, Korbet SM, Katz RS et al. Value of a complete or partial remission in severe lupus nephritis. Clin J Am Soc Nephrol 2008; 3: 46-53.
5. Korbet SM, Lewis EJ, Schwartz MM et al. Factors predictive of outcome in severe lupus nephritis. Am J Kidney Dis 2000; 35: 904-914.
6. Boumpas DT, Balow JE. Outcome criteria for lupus nephritis trials: a critical overview. Lupus 1998; 7: 622-629.
7. Chan TM, Tse KC, Tang CS et al. Long-term outcome of patients with diffuse proliferative lupus nephritis treated with prednisolone and oral cyclophosphamide followed by azathioprine. Lupus 2005; 14: 265-272.
8. Ioannidis JP, Boki KA, Katsorida ME et al. Remission, relapse, and re-remission of proliferative lupus nephritis treated with cyclophosphamide. Kidney Int 2000; 57: 258-264.
9. Houssiau FA, Vasconcelos C, D'Cruz D et al. Early response to immunosuppressive therapy predicts good renal outcome in lupus nephritis: lessons from long-term followup of patients in the Euro-Lupus Nephritis Trial. Arthritis Rheum 2004; 50: 3934-3940.
10. Lewis EJ, Hunsicker LG, Lan SP et al. A controlled trial of plasmapheresis therapy in severe lupus nephritis. N Engl J Med 1992; 326: 1373-1379.
11. Clough JD, Lewis EJ, Lachin JM et al.Rock G. Treatment protocols of the lupus nephritis collaborative study of plasmapheresis in severe lupus nephritis. Progress in Clinical and Biological Research 1990; Vol. 337New York, NYWiley-Liss301-307.
12. Tan EM, Cohen AS, Fries JF et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25: 1271-1277.
13. Churg J, Bernstein J, Glassock RJ Renal Disease: Classification and Atlas of Glomerular Disease 1995Tokyo, JapanIgaku-Shoin151-155.
14. Schwartz MM, Lan SP, Bonsib SM et al. Clinical outcome of three discrete histologic patterns of injury in severe lupus glomerulonephritis. Am J Kidney Dis 1989; 13: 273-283.
15. Schwartz MM, Bernstein J, Hill GS et al. Predictive value of renal pathology in diffuse proliferative lupus glomerulonephritis. Kidney Int 1989; 36: 891-896.
16. Weening JJ, D'Agati VD, Schwartz MM et al. The classification of glomerulonephritis in systemic lupus erythematosus revisited. J Am Soc Nephrol 2004; 15: 241-250.
17. Weening JJ, D'Agati VD, Schwartz MM et al. The classification of glomerulonephritis in systemic lupus erythematosus revisited. Kidney Int 2004; 65: 521-530.
18. Mok CC, Ying KY, Ng WL et al. Long-term outcome of diffuse proliferative lupus glomerulonephritis treated with cyclophosphamide. Am J Med 2006; 119: 355.e25-33
19. Mok CC, Ho CT, Chan KW et al. Outcome and prognostic indicators of diffuse proliferative lupus glomerulonephritis treated with sequential oral cyclophosphamide and azathioprine. Arthritis Rheum 2002; 46: 1003-1013.
20. Appel GB, Contreras G, Dooley MA et al. Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J Am Soc Nephrol 2009; 20: 1103-1112.
21. Chan TM, Li FK, Tang CS et al. Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. Hong Kong-Guangzhou Nephrology Study Group. N Engl J Med 2000; 343: 1156-1162.
22. Chan TM, Tse KC, Tang CS et al. Long-term study of mycophenolate mofetil as continuous induction and maintenance treatment for diffuse proliferative lupus nephritis. J Am Soc Nephrol 2005; 16: 1076-1084.
23. Ginzler EM, Dooley MA, Aranow C et al. Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N Engl J Med 2005; 353: 2219-2228.
24. Balow JE. Clinical presentation and monitoring of lupus nephritis. Lupus 2005; 14: 25-30.
25. Renal Disease Subcommittee of the American College of Rheumatology Ad Hoc Committee on Systemic Lupus Erythematosus Response Criteria. The American College of Rheumatology response criteria for proliferative and membranous renal disease in systemic lupus erythematosus clinical trials. Arthritis Rheum 2006; 54: 421-432.